Spruce Biosciences (SPRB) announced that the FDA has granted breakthrough therapy designation to tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB: